Paragraph 27 F1
Instructions for proper use of the product including in particular—
the dosage;
the method of use, application, administration or implantation and, if necessary, the route of administration;
the frequency of administration (including, if necessary, specifying the times at which the product may or must be administered);
the duration of treatment if this is to be time limited;
symptoms of an overdose and the action, if any, to be taken in the case of an overdose;
what to do if one or more doses have not been taken;
a specific recommendation to consult a doctor or pharmacist, as appropriate, for further explanation of the use of the product.
Annotations
Textual amendments
- F1
Sch. 27 Pt. 3 inserted (31.12.2020) by The Human Medicines (Amendment etc.) (EU Exit) Regulations 2019 (S.I. 2019/775), regs. 1, 204(6) (as amended by S.I. 2020/1488, reg. 1, Sch. 2 para. 158(e)); 2020 c. 1, Sch. 5 para. 1(1)
Notes on Part 3
Textual amendments
- F2
Words in Sch. 27 Pt. 3 heading omitted (1.1.2025) by virtue of The Human Medicines (Amendments relating to the Windsor Framework) Regulations 2024 (S.I. 2024/832), regs. 1(1), 143(c)